Explore Helsinn Advanced Synthesis' Largest Dedicated Anticancer Bay 
Helsinn Advanced Synthesis SA a Swiss pharmaceutical group focused on building quality cancer care and rare disease products, announces that its manufacturing subsidiary, Helsinn Advanced Synthesis SA (HAS), which develops and manufactures Active Pharmaceutical Ingredients (APIs), cGMP Advanced Intermediates, High Potency APIs (HPAPIs) and anticancer compounds, has opened its largest dedicated Anticancer bay at its manufacturing plant in Biasca, Switzerland. The new Anticancer bay is used for the development, analysis, and manufacturing of clinical and commercial anticancer APIs.
Our Facility 
Manufacturing
We’re committed to quality; it’s one of the core values that define how we work. We consistently upgrade our facilities to maintain our market leadership and to ensure they are the highest standard for producing medicines, and we are proud of our position as a global leader in the manufacture of medicines.
Road to HAS 2030
Anticancer API Facility
HAS plans our expansion to better serve unmet medical needs.
  • 2021-2023 - 8M QC Laboratory Center - State of the Art Technology.
  • 2022-2027 - Synthesis D - 70-80M 3 Production Bay.
  • 2027-2030 - Future production units TBD.
Confidence, Experience & Quality
Our extensive drug manufacturing experience is built on successfully transferring over 150 projects over the last three decades. Helsinn manufacturing supports a wide range of Chemistry, Manufacturing and Control (CMC) and regulatory activities pertaining to Good Manufacturing Practice (cGMP) production. More
Where To Meet HAS
About Helsinn
Helsinn is committed to quality; it’s one of the core values that define how we work. Because we consistently upgrade our facilities and maintain them to the highest standards for producing medicines, we can be proud of our position as a global leader in the manufacture of medicines.

Helsinn Advanced Synthesis
Today APIs, HPAPIs, and Anticancer API for third parties are developed and manufactured at our Biasca facility. Our state-of-the-art segregated facility has advanced containment technologies that protect the integrity of both our own products and those of our clients. HAS maintains a successful quality record with global regulatory agencies. More than half of our third-party clients have products that are NDA submitted or on the market. Our Biasca site has been ISO 14001 certified since 2000, showing our commitment towards environmental protection. Health and Safety OHSAS 18001 certified in 2005 (the first chemical plant in Switzerland to reach this standard).